Two Day Biomarkers Conference 2019 (London, United Kingdom - March 12-13, 2019)

Dublin, Dec. 12, 2018 (GLOBE NEWSWIRE) -- The "2nd Biomarkers Conference 2019" conference has been added to ResearchAndMarkets.com's offering.

2 days of informative, scientific and business development presentations, workshops, 1 to 1 meetings , speed networking sessions and interactive corporate exhibition.

Over 50 attendees representing leading pharmaceutical organisations and global biotechnology companies, and internationally renowned academic institutions

60 presentations, case studies, workshops and panel discussions focused on the key issues in biomarker drug discovery and development, clinical applications and companion diagnostics.

4 interactive streams:

• Biomarkers in Drug Discovery and Development
• Clinical Biomarker Assay Development
• Developing Companion Diagnostics
• Advancement in Biomarker Research

20 pre-scheduled one to one meetings, exhibition and informal networking opportunities

A Biomarker is an identifiable and measurable characteristic, which identifies the severity and/or occurrence of a specific disease. It has major applications in the discovery and development of novel therapeutic drugs. Generating annual sales of $17.5 billion in 2013. Global biomarkers, continue to play a vital role in the discovery and development of novel therapeutic drugs. Anticipated steady growth at an annual rate of 18.5% suggests the revenues will reach over $40.8 billion by 2018.

Primarily driven by the oncology market, the industry's window will significantly widen. In particular the need to screen and detect tumour cells earlier is expected to propel the market for oncology biomarkers, which is projected to grow at the highest rate over the next 5 years. Earlier detection can help eliminate the need for invasive treatments, often required when cancer is discovered at too late a stage.

Discovery technology advances, an increase in partnerships and collaborations to bolster biomarker research, a boost in government and private sector investments and funds for biomarker discovery, and FDA backing for biomarker development and the driving forces behind that trend. But the forecast report points out that challenges in the market still exist. For example the high capital investment and low benefit-cost ratio associated with biomarkers. The biomarker validation procedure is also burdensome, and sample collection and storage remain barriers to market growth.

The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S), GlaxoSmithKline, PLC, (UK), Siemens Healthcare (Germany), Aboott Laboratories, Inc (USA), GE Healthcare (U.K), Affymetrix, Inc (U.S), Thermo Fisher Scientific, Inc (U.S), Epigenomics AG (Germany), Eisai Co Ltd (Japan), Bio-Rad Laboratories, Inc (U.S), Eli Lilly and Company (U.S), Merck & Co. (U.S), Genomic Health Inc. (U.S), and Agilent Technologies Inc (U.S).

Agenda:

Day 1

08:30 - Coffee and registration - An opportunity to meet and to network with your conference colleagues.

09:30 - Chairperson opening remarks
Thomas Hach, Director of Healthcare Systems, Novartis

Biomarkers, Diagnostics and Clinical Research

BIOMARKERS IN DRUG DISCOVERY AND DEVELOPMENT

09:40 - Establishing the success and impact of biomarker research in drug development
Establishing the success of biomarker research in drug development.
Establishing the impact of biomarker research in drug development.
How to promote quality of development of biomarker research.

10:20 - Biomarker in drug discovery & development: chronic disease and onco-immunology
Biomarker in drug discovery
Development
Chronic disease
Onco-immunology

11:00 - Morning Coffee/Tea & Discussion

11:30 - Demonstrating the value of biomarker in drug industry
Analysis of Biomarker market
Market Dynamics
Market Demographics

CLINICAL BIOMARKER ASSAY DEVELOPMENT

11:50 - Clinical assay development- the process and considerations

Assessing assay development
What are the developmental measures in biomarker design
Are there levels of regulation
Consulsions/discussion

12:30 - Networking luncheon

13:40 - Panel Discussion - Clinical assay development for cancer protein biomarkers: what works and what does not work

Clinical assay development for cancer protein biomarkers
Clinical assay development -success stories
Clinical assay development - failure stories

14:30 - Best practices fit for purpose biomarker assay validation

Safety Issues - What is our current stand?
Initiating a new product using auto-contractable syringes, advantages
Initiating a new product using manual-retractable syringes, advantages

15:10 - Afternoon Tea/Coffee

15:30 - Incorporating assay development into an overall strategy
Changes legislative requirements
Safety device assembly machines-prefilled syringes
Maintaining quality and safety

16:10 - Application of key technologies for biomarker development

16:50 - Chairperson's closing remarks and end of conference

17:00 - 18:00 - Networking Drinks Session

Day 2

08:30 - Coffee and registration - An opportunity to meet and to network with your conference colleagues.

09:30 - Chairperson opening remarks
Thomas Hach, Director of Healthcare Systems, Novartis

Biomarkers, Diagnostics and Clinical Research

09:40 - Predictive biomarkers and companion diagnostics-value personalized medicine
Summary of biomarkers
Predictive biomarkers
Companion diagnostics
Value personalized medicine

10:20 - Integration of diagnostics into drug development
Drug development procedures
Integration of diagnostics
Approval Design Considerations
What are regulators looking at?
Trends and challenges

10:50 - Morning Coffee/Tea & Discussion

11:10 - The role of companion diagnostics in improving patient care
Role of companion diagnostics
Improving patient care
International regulations

11:50 - The business of successful companion diagnostic partnerships

12:30 - Networking luncheon

ADVANCEMENT IN BIOMARKER RESEARCH

13:30 - New Advances in biomarker technologies and platforms
New technological advances
Benefit of new platforms
What should we learn from previous hurdles
New approaches to managing biomarker development

14:10 - Advancing the use of biomarkers and pharmacogenomics in drug development

Advancing the use biomarkers
Commercial Success of biomarkers and pharmacogenomics
Considerations for: advancing drug development

14:50 - Safety assessment of Biomarkers
Safety regulations
Safety inspections
Safety legislation

15:20 - Afternoon Tea/Coffee

15:40 - Chip-based technology for detecting biomarkers
New chip based technology
Design Factors
Material Selection
Do we learn from previous experiences?

16:20 - Application of key technologies for Biomarker development
Current manufacturing practices in the EU & US
Enhancing communication between key technologies for biomarker development
Evaluate new technology
Evaluate market development

17:00 - 17:10 - Chairperson's closing remarks and end of the conference

For more information about this conference visit https://www.researchandmarkets.com/research/9m7dx9/two_day?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Biomarkers